Division of Hematology, Oncology and Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, United States.
Front Immunol. 2021 Jun 10;12:688460. doi: 10.3389/fimmu.2021.688460. eCollection 2021.
Survival after solid organ transplantation (SOT) is limited by chronic rejection as well as the need for lifelong immunosuppression and its associated toxicities. Several preclinical and clinical studies have tested methods designed to induce transplantation tolerance without lifelong immune suppression. The limited success of these strategies has led to the development of clinical protocols that combine SOT with other approaches, such as allogeneic hematopoietic stem cell transplantation (HSCT). HSCT prior to SOT facilitates engraftment of donor cells that can drive immune tolerance. Recent innovations in graft manipulation strategies and post-HSCT immune therapy provide further advances in promoting tolerance and improving clinical outcomes. In this review, we discuss conventional and unconventional immunological mechanisms underlying the development of immune tolerance in SOT recipients and how they can inform clinical advances. Specifically, we review the most recent mechanistic studies elucidating which immune regulatory cells dampen cytotoxic immune reactivity while fostering a tolerogenic environment. We further discuss how this understanding of regulatory cells can shape graft engineering and other therapeutic strategies to improve long-term outcomes for patients receiving HSCT and SOT.
实体器官移植(SOT)后的存活率受到慢性排斥反应的限制,以及需要终身免疫抑制及其相关毒性的限制。一些临床前和临床研究已经测试了旨在诱导无终身免疫抑制的移植耐受的方法。这些策略的有限成功导致了将 SOT 与其他方法(如同种异体造血干细胞移植(HSCT))相结合的临床方案的发展。在 SOT 之前进行 HSCT 可以促进能够驱动免疫耐受的供体细胞的植入。最近在移植物处理策略和 HSCT 后免疫治疗方面的创新为促进耐受和改善临床结果提供了进一步的进展。在这篇综述中,我们讨论了 SOT 受者中免疫耐受发展的常规和非常规免疫机制,以及它们如何为临床进展提供信息。具体来说,我们回顾了最近阐明哪些免疫调节细胞抑制细胞毒性免疫反应同时促进耐受环境的机制研究。我们进一步讨论了如何理解调节细胞可以塑造移植物工程和其他治疗策略,以改善接受 HSCT 和 SOT 的患者的长期结果。